Table 2.

Patient and sample incidence of T-VEC DNA during cycles 1–4.

	Patient incidence of T-VEC DNA			Sample incidence of T-VEC DNA
	Baseline HSV-1 seronegative	Baseline HSV-1 seropositive	Overall	Baseline HSV-1 seronegative	Baseline HSV-1 seropositive	Overall
	N = 17	N = 40	N = 60	n3/n4 (%)	n3/n4 (%)	n3/n4 (%)
	n1/n2 (%)	n1/n2 (%)	n1/n2 (%)
Blood	17/17 (100·0)	39/40 (97·5)	59/60 (98·3)	136/297 (45.8)	234/693 (33.8)	383/1043 (36.7)
Urine	5/17 (29·4)	14/40 (35·0)	19/60 (31·7)	9/294 (3.1)	22/694 (3·2)	31/1041 (3·0)
Surface of injected lesions	17/17 (100·0)	40/40 (100·0)	60/60 (100·0)	165/307 (53·7)	507/885 (57·3)	726/1260 (57·6)
Exterior of occlusive dressings	13/17 (76·5)	33/40 (82·5)	48/60 (80·0)	51/289 (17·6)	145/741 (19·6)	212/1085 (19·5)
Oral mucosa	3/17 (17·6)	1/40 (2·5)	5/60 (8·3)	7/105 (6.7)	1/237 (0·4)	9/359 (2·5)
Anogenital area	0/7 (0·0)	2/16 (12·5)	2/25 (8·0)	0/53 (0·0)	2/121 (1·7)	2/190 (1·1)

N = Number of patients in the analysis set; n1 = number of patients with positive qPCR testing result; n2 = number of patients with samples collected; n3 = number of samples with positive qPCR testing result; n4 = number of samples collected.

Abbreviations: HSV, herpes simplex virus; qPCR, quantitative polymerase chain reaction; T-VEC, talimogene laherparepvec.